Balyasny Asset Management
AXSM icon

Balyasny Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Balyasny Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,431
Closed -$2.59M – 2818
2025
Q1 		$2.85M Sell
24,431
-156,782
-87% -$17.9M ﹤0.01% 1521
2024
Q4 		$15.3M Buy
181,213
+119,046
+191% +$10.9M 0.02% 777
2024
Q3 		$5.59M Buy
+62,167
New +$5.43M 0.01% 1203
2024
Q2 		– Sell
-9,606
Closed -$767K – 2568
2024
Q1 		$767K Buy
+9,606
New +$806K ﹤0.01% 1903
2023
Q1 		– Sell
-120,874
Closed -$9.32M – 2643
2022
Q4 		$9.32M Buy
+120,874
New +$7.22M 0.03% 773
2021
Q4 		– Sell
-44,509
Closed -$1.47M – 2223
2021
Q3 		$1.47M Buy
+44,509
New +$1.73M 0.01% 1216
2020
Q4 		– Sell
-33,268
Closed -$2.37M – 1320
2020
Q3 		$2.37M Buy
+33,268
New +$2.59M 0.02% 794
2018
Q2 		– Sell
-14,050
Closed -$34K – 1774
2018
Q1 		$34K Buy
+14,050
New +$42.1K ﹤0.01% 1871

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's AXSM Position: Q2 2025 in Review

Balyasny Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 24,431 shares — an estimated $2.59M sold.

Balyasny Asset Management first reported a position in AXSM in Q1 2018 and held it in 8 quarters. The position peaked at $15.3M in Q4 2024. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Balyasny Asset Management reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 24,431 Axsome Therapeutics shares in Q2 2025, an estimated $2.59M.
  • Balyasny Asset Management first reported a position in Axsome Therapeutics in Q1 2018 and held it in 8 quarters.
  • Balyasny Asset Management's Axsome Therapeutics position peaked at $15.3M in Q4 2024.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.